| Bioactivity | Benzosceptrin C is an inhibitor for PD-L1, which promotes programmed cell death ligand (PD-L1) degradation in a lysosomal pathway, enhances the cytotoxicity of T-cells and exhibits antitumor activity[1]. |
| Invitro | Benzosceptrin C (0-10 μM) 抑制 CRC 癌细胞中的 PD-L1 表达，通过破坏 PD-L1 检查点增强 T 细胞的细胞毒性，并抑制 CRC 癌细胞 RKO 和 HCT116 的增殖[1]。Benzosceptrin C (0-10 μM) 通过抑制 DHHC3 的活性阻断 PD-L1 的棕榈酰化，从而促进 PD-L1 的溶酶体降解，阻断 PD-L1 与 PD-1 的直接相互作用，发挥免疫抗肿瘤作用[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Benzosceptrin C 相关抗体: Cell Proliferation Assay[1] Cell Line: |
| In Vivo | Benzosceptrin C (5-50 mg/kg/day，腹腔注射，16 天) 通过激活肿瘤浸润 T 细胞和诱导细胞凋亡 (apoptosis) 抑制 MC38 异种移植 C57BL/6 小鼠的肿瘤生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1204605-36-6 |
| Formula | C22H18Br4N10O2 |
| Molar Mass | 774.06 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wang Q, et al., Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3. Cell Rep Med. 2024 Feb 20;5(2):101357. |